323

Эпидемиологические исследования тиомерсала и аутизма: P. Stehr-Green, P. Tull, M. Stellfeld, et al., Autism and Thimerosal-Containing Vaccines: Lack of Consistent Evidence for an Association, American Journal of Preventive Medicine 25 (2005): 101–106; K. M. Madsen, M. B. Lauritsen, C. B. Pedersen, et al., Thimerosal and the Occurrence of Autism: Negative Ecological Evidence from Danish Population-Based Data, Pediatrics 112 (2003): 604–606; A. Hviid, M. Stellfeld, J. Wohlfahrt, and M. Melbye, Association Between Thimerosal-Containing Vaccine and Autism, Journal of the American Medical Association 290 (2003): 1763–1766; J. Heron and J. Golding, Thimerosal Exposure in Infants and Developmental Disorders: A Prospective Cohort Study in the United Kingdom Does Not Support a Causal Association, Pediatrics 114 (2004): 577–583; N. Andrews, E. Miller, A. Grant et al., Thimerosal Exposure in Infants and Developmental Disorders: A Retrospective Cohort Study in the United Kingdom Does Not Support a Causal Association, Pediatrics 114 (2004): 584–591; E. Fombonne, R. Zakarian, A. Bennett, et al., Pervasive Developmental Disorders in Montreal, Quebec, Canada: Prevalence and Links with Immunization, Pediatrics 118 (2006): 139–150; W. W. Thompson, C. Price, B. Goodson, et al., Early Thimerosal Exposure and Neuropsychological Outcomes at 7 to 10 Years, New England Journal of Medicine 357 (2007): 1281–1292; R. Schechter and J. Grether, Continuing Increases in Autism Reported to California’s Development Services System, Archives of General Psychiatry 65 (2008): 19–24.